L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The major impact of this study will be to identify the adult severe asthma cohort that will
benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of
adult severe asthma patients will respond to supplemental L-arginine and derive clinical
benefit from the addition of this therapy to standard-of-care asthma medications. The
investigators hypothesize that the patients that benefit most will have low exhaled nitric
oxide concentrations (< 20 ppb) at baseline.